AAGP™ >>
AAGPs™ were invented by Dr. Geraldine-Castelot-Deliencourt and developed and protected by patents in partnership with the Institute for Scientific Application (INSA) of France. For her work in this area Dr. Castelot-Deliencourt was honored in 2006 with France's highest award for scientific accomplishment - the Francinov Award.
PROTOKINETIX
ProtoKinetix’ Anti-Aging Glycopeptides (AAGPs™) have demonstrated a unique bioactive ability to increase the survival and viability of living cells. These cells are expensive and are the key inventory in Regenerative Medicine.
As Regenerative Medicine continues to play a more and more important role in the treatment of diseases cell survival solutions are required.
ProtoKinetix’ lead AAGP™ molecule is small, stable, non-toxic and bioactive. It can be used as a tool to increase cell inventory and has potential applications where inflammation, oxidation, radiation, nutrient deprivation and cryopreservation are stresses causing cell death and accelerated aging.
ProtoKinetix has test data which demonstrates AAGP™ attributes and is documented on this site.
Although AAGP™ has multiple biomedical applications; ProtoKinetix is not in the applications business. It is in the molecule business. As such, ProtoKinetix is actively seeking collaborators to develop applications.
PRESS RELEASES >>
DEC 07, 2011
Italian Laboratory Expands ProtoKinetix' Market for AAGP™
SEP 21, 2011
ProtoKinetix Receives Excellent Results from the University of British Columbia Eye Inflammation Study
AUG 18, 2011
ProtoKinetix Launches Sales of AAGP™ as a Tool to Protect Cells in Research
MAY 04, 2011
ProtoKinetix President and CEO to be Interviewed Live
